Manuel Vaz Silva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3526573/publications.pdf

Version: 2024-02-01

567281 552781 30 871 15 26 citations h-index g-index papers 31 31 31 1322 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pharmacokinetic and safety profile of <i>trans</i> à€resveratrol in a rising multipleâ€dose study in healthy volunteers. Molecular Nutrition and Food Research, 2009, 53, S7-15. | 3.3 | 363 |
| 2 | Why healthy subjects volunteer for phase I studies and how they perceive their participation?. European Journal of Clinical Pharmacology, 2007, 63, 1085-1094. | 1.9 | 65 |
| 3 | Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. European Journal of Clinical Pharmacology, 2014, 70, 1059-1071. | 1.9 | 58 |
| 4 | Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093). Drugs in R and D, 2005, 6, 201-206. | 2.2 | 48 |
| 5 | Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Research, 2013, 105, 368-376. | 1.6 | 39 |
| 6 | Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia, 2013, 54, 1453-1461. | 5.1 | 38 |
| 7 | Etamicastat, a Novel Dopamine \hat{l}^2 -Hydroxylase Inhibitor: Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Hypertension. Clinical Therapeutics, 2013, 35, 1983-1996. | 2.5 | 29 |
| 8 | Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study. Journal of Clinical Pharmacology, 2012, 52, 222-233. | 2.0 | 27 |
| 9 | Bioavailability and Bioequivalence of??Two Enteric-Coated Formulations of??Omeprazole in Fasting and Fed Conditions. Clinical Drug Investigation, 2005, 25, 391-399. | 2.2 | 26 |
| 10 | Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundamental and Clinical Pharmacology, 2009, 23, 509-514. | 1.9 | 26 |
| 11 | Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-Î ² -Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects. Drugs in R and D, 2010, 10, 225-242. | 2.2 | 23 |
| 12 | Pharmacokinetic?pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. European Journal of Clinical Pharmacology, 2003, 59, 603-609. | 1.9 | 22 |
| 13 | Singleâ€Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5–453), a New Dopamine βâ€Hydroxylase Inhibitor, in Healthy Subjects. Journal of Clinical Pharmacology, 2012, 52, 156-170. | 2.0 | 21 |
| 14 | Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa. Clinical Neuropharmacology, 2004, 27, 17-24. | 0.7 | 15 |
| 15 | Pharmacokinetics and Tolerability of Etamicastat Following Single and Repeated Administration in Elderly Versus Young Healthy Male Subjects: An Open-Label, Single-Center, Parallel-Group Study. Clinical Therapeutics, 2011, 33, 776-791. | 2.5 | 15 |
| 16 | Pharmacokineticâ€"pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Clinical Therapeutics, 2009, 31, 2258-2271. | 2.5 | 13 |
| 17 | Alterações eletrocardiográficas benignas e patológicas em atletas. Revista Portuguesa De Cardiologia, 2015, 34, 753-770. | 0.5 | 9 |
| 18 | Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453). Drugs in R and D, 2011, 11, 127-136. | 2.2 | 7 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. European Journal of Clinical Pharmacology, 2008, 64, 961-966. | 1.9 | 6 |
| 20 | Chronopharmacology of nebicapone, a new catechol- <i>O</i> -methyltransferase inhibitor. Current Medical Research and Opinion, 2010, 26, 1097-1108. | 1.9 | 5 |
| 21 | Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200Âmg/50Âmg. Drugs in R and D, 2008, 9, 435-446. | 2.2 | 4 |
| 22 | Cardiac safety profile of etamicastat, a novel peripheral selective dopamine- \hat{l}^2 -hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. IJC Metabolic & Endocrine, 2015, 7, 10-24. | 0.5 | 4 |
| 23 | Unusual type A aortic dissection. Revista Portuguesa De Cardiologia, 2012, 31, 175-176. | 0.5 | 2 |
| 24 | MONITORIA: The start of a new era of ambulatory heart failure monitoring? Part II – Design. Revista Portuguesa De Cardiologia, 2021, 40, 343-351. | 0.5 | 2 |
| 25 | Peripheral arterial tonometry as a method of measuring reactive hyperaemia correlates with organ dysfunction and prognosis in the critically ill patient: a prospective observational study. Journal of Clinical Monitoring and Computing, 2021, 35, 1169-1181. | 1.6 | 1 |
| 26 | MONITORIA: The start of a new era of ambulatory heart failure monitoring? Part I – Theoretical Rationale. Revista Portuguesa De Cardiologia, 2021, 40, 329-337. | 0.5 | 0 |
| 27 | Abstract 358: Signature microRNA Expression Pattern of Essential Hypertension in a Portuguese Population. Hypertension, 2012, 60, . | 2.7 | O |
| 28 | Identifications of Novel SNPs in Portuguese Essential Hypertensive Patients. FASEB Journal, 2013, 27, 874.14. | 0.5 | 0 |
| 29 | Analysis of MicroRNA Expression Profile in PBMCs of Hypertensive Patients. FASEB Journal, 2013, 27, 737.3. | 0.5 | 0 |
| 30 | Effects of enalapril and imidapril in the capsaicin cough challenge test and spirometry parameters in healthy volunteers. Therapy: Open Access in Clinical Medicine, 2004, 1, 223-230. | 0.2 | 0 |